A study of more than 10,000 patients illuminated the characteristics and needs of patients who are in remission. Learn how an innovative rehabilitation model improved clinical outcomes and patient satisfaction with nursing care. Learn about the diverse unmet needs and potential solutions related to the experiences of patients and caregivers. A subgroup analysis of CARTITUDE-4 evaluated ciltacabtagene autoleucel in functionally high-risk multiple myeloma. The survey results will be used to formulate recommendations to improve patient involvement in decision making. Nurses may be able to play a role in aligning views between patients and hematologists on prognosis and goals of care. The approval is for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for ASCT. The approval is supported by data from the phase III PERSEUS study. An expert shares his insights on the challenges and practical considerations that come with bispecific antibody treatment. Currently, there is no standardization of melphalan administration. A real-world study presented at the EHA 2024 Congress provided insights on patient and caregiver experiences. The risk of hospitalization was associated with the number of drugs in a patient's myeloma treatment regimen. With 3 FDA-approved BiTEs for myeloma, oncology nurses must be able to understand BiTEs and explain them to patients. Talquetamab is a T-cell redirecting bispecific antibody targeting GPRC5D on myeloma cells. Due to the unique challenges associated with administering these therapies, a team aimed to standardize the workflow. Misinformation or fake news can mislead patients with multiple myeloma. Nurse researchers noted patients had “feelings of confusion at the time of initial diagnosis" of multiple myeloma. The study showed that nursing support was a “key environmental facilitator" for physical activity in these patients. Although CRAB describes end-organ symptoms of multiple myeloma, it does not provide a full picture. Myeloma is a complex blood cancer that can be difficult to comprehend, especially the 2 earlier precursor disease stages.